HIGHLIGHTS
- who: Toshihiko Matsumoto and collaborators from the Department of Medical Oncology, Kobe City Medical Center General Hospital, Treatment Center, Kansai Medical University, Shinmachi, Hirakata, Japan have published the paper: Real-World Data of Trastuzumab Deruxtecan for Advanced Gastric Cancer: A Multi-Institutional Retrospective Study, in the Journal: (JOURNAL)
- what: Following this trial, a randomized phase II trial (DESTINY-Gastric01) was conducted. This study showed that PFS was longer in patients who received prior ICIs than that in other patients, whereas OS tended to be longer. In the study , genome profiling using next-generation sequencing was . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.